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Chemokines have received increasing attention due to their inhibitory activities on human immunodeficiency virus type-1
(HIV-1) and simian immunodeficiency virus (SIV) replication and the potential for chemokine receptors to assist in HIV-1/SIV
entry into permissive cells. Besides CD4, which is the major receptor for HIV-1 and SIV, a number of chemokine receptors
including but not limited to APJ, CCR3, CXCR4, and CCR5 may be coreceptors for HIV-1/SIV, not only in peripheral blood and
lymphoid tissues but also in the central nervous system (CNS). The present studies reveal the lack of CD4, but the significant
expression of various chemokine receptors, APJ, CCR3, CXCR4, and CCR5, plus C-type lectins DC-SIGN and L-SIGN on
isolated primary human brain microvascular endothelial cells (MVECs). As these MVECs do not express CD4, this suggests
a CD4-independent HIV/SIV entry/infection of these cells, which are the major cells constituting the human blood–brain
barrier. We also found that chemokines for cognate chemokine receptors individually were unable to block binding of HIV-1
to brain MVECs. These results reveal that in primary isolated brain MVECs viral attachment is mediated by a possible
previously unknown receptor(s) or by cooperative activity of various receptors. Moreover, mRNA transcripts for DC-SIGN/
L-SIGN, as well as DC-SIGN protein expression, suggest the capability of MVECs to attach viral particles on cell surfaces,
even though polyclonal antisera for DC-SIGN did not affect viral binding to these cells. These data will assist in furtherINTRODUCTION
Human immunodeficiency virus type-1 (HIV-1) infec-
tion leads to up-regulation of various chemokines in
humans and simian brain tissues (Schmidtmayerova et
al., 1996; Westmoreland et al., 1998). Elevated concen-
trations of -chemokines in cerebrospinal fluid (CSF) of
HIV-1-seropositive individuals also suggest a major role
for chemokines and their cognate receptors in the patho-
genesis of neuroAIDS (Cinque et al., 1998b; Kelder et al.,
1998). Recent data have demonstrated that chemokine
and chemokine-receptor expression may be extremely
important in understanding a variety of diseases of the
primate and human central nervous system (CNS). Che-
mokines, which were first shown as chemoattractant
agents in the immune system and for hematopoietic
cells, have now been demonstrated clearly to be ex-
pressed differentially in the CNS (Glabinski et al., 1995).
Moreover, a number of studies demonstrating that cer-
tain chemokines are capable of suppressing HIV-1/SIV
infection, and that chemokine receptors function as co-
receptors for HIV-1/SIV entry into permissive cells, have
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All rights reserved.assisted in revealing several previous mysteries of HIV-1
pathogenesis (BouHamdan et al., 2001; Cocchi et al.,
1995; Deng et al., 1996; He et al., 1997; Virelizier, 1999). It
has been reported previously that lentivirus infection of
the CNS induces neurological diseases in both humans
and animals (Kolson et al., 1998). In particular, the pres-
ence of HIV-1 in CSF and CNS-based cells suggests the
need for further exploration of viral entry into the brain
and the role of the brain protective sheath, the blood–
brain barrier (BBB), in the neuropathogenesis of HIV-1
infection.
The physiological functions of chemokines range from
signal transduction to brain development and mainte-
nance of normal brain homeostasis (Klein et al., 1999;
Lazarini et al., 2000; Zheng et al., 1999; Zhou et al., 1998).
As far as CNS pathology is concerned, chemokines are
involved in a number of neurodegenerative disorders,
such as multiple sclerosis, strokes, Alzheimer’s disease,
AIDS-related dementia, and brain tumors (Desbaillets et
al., 1994; Gironi et al., 2000; Kuratu, 1999; Langford and
Masliah, 2001; Lukiw and Bazan, 2000). Most of the
chemokines’ activities are mediated through their recep-
tors, which are members of a superfamily of G-protein-
coupled proteins (Baggiolini, 1998).understanding lentiviral entry into the CNS. © 2002 Elsevier
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DC/L-SIGNs are type II membranous proteins with78Science
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characteristic external mannose-binding, C-type lectin
domains (Steinman, 2000). The isolation and character-
ization of these glycoproteins are based on their capacity
to bind the glycan-rich HIV-1 envelope in a CD4-indepen-
dent manner (Curtis et al., 1992). The role of DC-SIGN
and L-SIGN in HIV-1 pathogenesis has been highlighted
by recent studies demonstrating the capability of X4, R5,
and X4R5 HIV-1 strains to bind DC-SIGN and increase
further viral transmission to permissive cells. Of note,
viral binding and transmission were critically dependent
on surface expression of these moieties in transmitting
cells (Pohlmann et al., 2001).
Therefore, to gain a better understanding of the roles
of various receptors and ligands involved in HIV-1/SIV
entry into the CNS, we analyzed the repertoire of their
mRNAs, expressed by primary isolated human brain mi-
crovascular endothelial cells (MVECs). Furthermore, the
mRNA expression findings were substantiated with im-
munocytochemical analyses of the respective mRNA
product protein on the cell surface. The functionality of
the independent receptor/ligands was explored with re-
spective blocking agents for each of the chemokine
receptors, as well as polyclonal anti-DC-SIGN antiserum.
Our studies reveal that primary isolated human brain
MVECs express a number of diverse chemokine recep-
tors, such as CCR3, CXCR4, CCR5, and APJ. Moreover,
these cells also express DC-SIGN and L-SIGN glycopro-
teins, which are being actively investigated for their role
in HIV-1 entry and infection. We were unable to block
viral surface binding on primary MVECs with chemokine
receptor cognate ligands, as well as with DC-SIGN poly-
clonal antiserum. We conclude that brain MVECs ex-
press diverse chemokine receptors known for potential
HIV-1/SIV entry; however, none of these receptors inde-
pendently can control the virion attachment on the sur-
face of these BBB-based cells and cellular entry.
RESULTS
Reverse transcriptase-polymerase chain reaction
(RT-PCR) analyses of HIV-1/SIV coreceptors
on primary isolated human brain MVECs
The presence of HIV-1 in CSF and various CNS-based
cells suggests that these cells are potential targets for
HIV-1/SIV infection and as transfer moieties to other CNS
elements (Cinque et al., 1998a; Di Stefano et al., 1997,
1998; Enting et al., 2001; Hengge et al., 1998; McArthur et
al., 1997; Price, 2000). It has become established that
chemokine receptors, CXCR4 and CCR5, act as major
coreceptors together with CD4 for HIV-1 entry into di-
verse target cells (Deng et al., 1996). CD4-independent
and chemokine (CXCR4, CCR5)-dependent infection of
various cells suggests the capability of certain HIV-1
isolates to infect cells devoid of CD4 but with functional
chemokine coreceptors (Edinger et al., 1997b; Edwards
et al., 2001). The BBB, with its MVECs, is the first line of
defense against viral entry into brain. Of note, several
previous reports suggest HIV-1 infection of human brain
MVECs and astrocytes via CD4-independent mecha-
nisms (Moses et al., 1993, 1996, 1997; Moses and Nel-
son, 1994; Schweighardt et al., 2001).
Based on these previous findings, we examined pri-
mary isolated human brain MVECs for the presence of
chemokine receptor CCR3, CXCR4, CCR5, and APJ
mRNAs. We also explored whether DC-SIGN and L-SIGN
mRNAs exist in human brain MVECs. As internal con-
trols, we utilized von Willebrand factor (Factor VIII), spe-
cific for endothelium, and GAPDH mRNA. The primers
used for amplification of each receptor, as well as con-
trols, are described in Table 1. Of note, our RT-PCR
amplicon sizes were in agreement with expected sizes
for each PCR product: von Willebrand factor, GAPDH,
APJ, CCR3, CXCR4, CCR5, CD4, DC-SIGN, and L-SIGN at
323, 309, 481, 417, 522, 339, 462, 347, and 418 bases,
respectively. To further confirm the specificity of each
amplicon, we performed Southern blotting for each of the
amplified products by utilizing an internal sense probe
for the PCR product. Table 2 describes various probes
used for Southern blotting analyses of each of the recep-
tors’ cDNA, as well as controls. As shown in Fig. 1,
primary isolated human brain MVECs do not express
CD4 mRNA, the major receptor for HIV-1 attachment and
cell entry. However, primary MVECs express mRNA for
APJ, CCR3, CXCR4, and CCR5 chemokine receptors (Fig.
1). These findings suggest that HIV-1 attachment and
entry in human brain MVECs possibly involve a CD4-
independent mechanism, utilizing either one or multiple
chemokine receptors. These results corroborate the pre-
vious reports describing CD4-independent, CCR5-de-
pendent infection of simian brain capillary endothelial
cells (Edinger et al., 1997a) and reports showing that
human brain MVECs could be infected with HIV-1
(Mukhtar et al., 2000; Mukhtar and Pomerantz, 2000).
For assessing differential expression of DC-SIGN and
L-SIGN, we aligned cDNA sequences of DC-SIGN and
L-SIGN. Figure 2 shows the alignment of these two cDNA
sequences. As demonstrated in Fig. 2, it is possible to
generate primers that can differentially amplify cDNA for
DC-SIGN and L-SIGN. The respective sense and antisense
primers used for differential amplification of DC-SIGN and
L-SIGN are described in Table 1 and Fig. 2. As shown in
Fig. 1, we observed transcripts for both DC-SIGN and L-
SIGN in primary brain MVECs, even though the message
for DC-SIGNwasmore predominant than L-SIGN. Thus, the
expression of DC-SIGN and L-SIGN on MVECs could be
advantageous for viral entry into the brain.
Immunocytochemistry for receptors on primary
isolated human brain MVECs
To further confirm the presence of various HIV-1/SIV
coreceptors on primary brain MVECs, we extended the
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RT-PCR findings with immunocytochemical analyses of
the cells for each of the receptors. Before immunocyto-
chemical analyses were performed, each batch of pri-
mary isolated brain MVECs was characterized for ex-
pression of von Willebrand factor, a marker expressed on
MVECs. Approximately 97% von Willebrand factor-pos-
itive cells were used for further exploration of chemokine
receptors. Of note, in our experience, we have found that
primary brain MVECs lose their endothelial markers with
multiple passages (not illustrated). The present study’s
observations are based on MVECs only at the third
passage. We utilized secondary antibodies alone as neg-
ative controls for these analyses.
A granular cytoplasmic expression of von Willebrand
factor confirmed the purity of these cells (Fig. 3A). CCR5,
CCR3, and CXCR4 were demonstrated on human brain
MVECs in these studies (Fig. 3A). Among the three re-
ceptors demonstrated in Fig. 3A, we observed higher
expression of CXCR4, as compared with CCR3 and
CCR5. Although this observation cannot be further sub-
stantiated due to variations in antibody affinity with each
of the antigens, by utilizing different antibodies from
various sources for each of the chemokine receptors, we
obtained a constant and reproducible expression pattern
(data not illustrated). Figure 3B shows immunocytochem-
ical data that APJ, one of the chemokine receptors whose
ligand, Apelin-36, has been described recently (Cay-
abyab et al., 2000), and DC-SIGN are also produced and
expressed on these cells. Of note, a specific antibody for
L-SIGN is not yet available.
HIV-1 binding to brain MVECs treated with selected
chemokines, soluble CD4, and polyclonal DC-SIGN
antiserum
To explore the functional role of each chemokine re-
ceptor toward lentiviral binding on the surface of human
brain MVECs, we blocked each receptor with inhibitory
concentrations of each chemokine and then exposed
them to X4, R5, and dual-tropic HIV-1 isolates. The inhib-
itory concentrations of chemokines were based on ear-
lier reports (Cayabyab et al., 2000; Cocchi et al., 1995; He
TABLE 1
Primers Used for Chemokine Receptor RT-PCRs from Human Brain MVECs
Gene Accession No./Reference Primer Sequence Amplicon size (bases)
von Willebrand’s factor Sense 5GGCTCAAGGACCGGAAGCGA3 323
Antisense 5GGCCTTGTTCTCAGGGGCCTG3
GAPDH NM_002046 Sense 5CGGAGTCAACGGATTTGGTCGTAT3 309
Antisense 5AGCCTTCTCCATGGTGGTGAAGAC3
APJ O’Dowd et al. (1993) Sense 5TACACAGACTGGAAATCCTCG3 481
Antisense 5TGCACCTTAGTGGTGTTCTCC3
CCR3 AF026535 Sense 5ATAGCTGGAGGCATTTCCACAC3 417
Antisense 5GAAGGAATGGGATGTATCTGCC3
CXCR4 AF025375 Sense 5CCTCCTCTTTGTCATCACGCTT3 522
Antisense 5CCAATGTAGTAAGGCAGCCAAC3
CCR5 U54994 Sense 5CTTCATCATCCTCCTGACAATC3 339
Antisense 5CTCTTCTTCTCATTTCGACACC3
CD4 M35160 Sense 5GTGGCACCTGGACATGC3 462
Antisense 5GGTCCCCACACCTCACA3
DC-SIGN ALIGN_000098.dat Sense 5GCTGACCCGGCTGAAGGC3 347
Antisense 5GGTGAGCCGTCCACCCATT3
L-SIGN ALIGN_000098.dat Sense 5CAGTGGCATCAGACTTTTTC3 418
Antisense 5CCTGGTAGATCTCCTGCA3
TABLE 2
Probes Used for RT-PCR Amplicon’s Southern Blotting from Human Brain MVECs
1. vWF 5GCAAGATCGACCGCCCTGAAGCCTCCCGCA3 (30-mer)
2. GAPDH 5GGGCGATGCTGGCGCTGAGTACGTCGTGGA3 (30-mer)
3. CD4 5GGCGAGCTGTGGTGGCAGGCGGAGAGGGCT3 (30-mer)
4. APJ 5CCTTCTTCTGCAAGCTCAGCAGCTACCTC3 (29-mer)
5. CCR3 5GACCATCTTCTGTCTCGTTCTCCCTCTGCTCG3 (32-mer)
6. CXCR4 5GGATCCCTGCCCTCCTGCTGACTATTCCCG3 (30-mer)
7. CCR5 5GGGGCTGGTCCTGCCGCTGCTTGTCATGGT (30-mer)
8. DC-SIGN 5GCTGAGGAGCAGAACTTCCTACAGCTGCAGT3 (31-mer)
9. L-SIGN 5CCAGAACCTGACCCAGCTTAAAGCTGCAGT3 (30-mer)
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et al., 1997). The APJ ligands, Apelin-36 (120 M), CCR3
ligand eotaxin (500 ng/ml), CXCR4 ligand SDF-1- (2.5
g/ml), and a mixture of CCR5 ligands MIP-1- MIP-1-,
and RANTES, each at a concentration of 500 ng/ml, were
used for blocking respective chemokine receptors. For
DC-SIGN, 1:5 diluted polyclonal anti-DC-SIGN antiserum
was used, whereas a soluble CD4 concentration of 20
g/ml was utilized. The epitope used to generate the
polyclonal antiserum is conserved between DC-SIGN
and L-SIGN. Figure 4 reveals HIV-1 p24 antigen binding
of various HIV-1 strains compared with an untreated
control. As shown, none of the chemokines blocked viral
binding on brain MVECs. Even though primary brain
MVECs are devoid of CD4 receptor, we also used solu-
ble CD4 to analyze the effects on virion binding on the
surface of these cells. Interestingly, compared with con-
trols we observed a larger amount of virus attached to
soluble CD4-treated cells (see below).
We demonstrated mRNA, as well as protein, for DC-
SIGN on primary isolated brain MVECs. Previously, DC-
SIGN has been shown to attach viral particles to cells
(Geijtenbeek et al., 2000a,b; Pohlmann et al., 2001). To
investigate the role of DC-SIGN on brain MVECs, we
utilized polyclonal DC-SIGN antiserum for blocking of
this receptor before exposing these cells to viruses. It
was shown that DC-SIGN antiserum did not block viral
binding, further suggesting some yet unknown receptor
involvement in binding of lentivirions to brain MVECs
(Fig. 4).
We observed significantly enhanced binding of the
macrophage-tropic (CCR5) Bal and dual-tropic (CCR5/
CXCR4) 89.6 virions on brain MVECs treated with Apelin-
36, a ligand for the APJ receptor, and soluble CD4 (Fig. 4).
Previously, Apelin-36 has been shown to inhibit viral
replication of macrophage and dual-tropic HIV-1 strains
(Cayabyab et al., 2000). Nonetheless, there are no pre-
vious reports showing such a phenomenon in primary
human isolated cells. However, in CD4 T-cells, several
CC-chemokines increased the replication of T-cell-tropic
viral strains (Kinter et al., 1998). This dichotomous effect
of chemokines has been ascribed to a signaling mech-
anism through inhibitory guanine nucleotide-binding reg-
ulatory proteins. Whether a similar mechanism operates
in brain MVECs requires further study.
The binding assay also reveals that only macrophage
(R5) and dual-tropic (X4R5) virions could attach to human
brain MVECs. As far as the X4-tropic strain NL4-3 was
concerned, we did not observe any significant binding in
the control, as well as in various ligand-treated cells (Fig.
4). These observations also support the previous reports
FIG. 2. Alignment of L-SIGN with DC-SIGN mRNA utilized to select
primers for differential expression of L-SIGN and DC-SIGN from human
brain MVECs. The forward arrow (A) shows the sense primer utilized to
differentially amplify L-SIGN with an antisense primer from the homol-
ogous region of both mRNAs. Forward arrow (B) shows the DC-SIGN
sense primer used to amplify only DC-SIGN mRNA transcripts. This
alignment has been submitted to EMBL. The accession number for this
alignment is ALIGN_000098.dat (alignment of DC-SIGN with L-SIGN
cds. submitted by M. Mukhtar, April 5, 2001).
FIG. 1. RT-PCR analysis of various receptors’ expression from pri-
mary isolated human brain MVECs. Various chemokine receptor tran-
scripts were amplified from cDNA, generated from total RNA utilizing
oligo(dT) primer. The specificity of each primer pair was confirmed by
DNA PCR utilizing the respective plasmid DNA for each receptor. Lanes
1 and 2 show internal controls for von Willebrand factor and GAPDH
mRNA. Lanes 3–6 include the chemokine receptors APJ, CCR3, CXCR4,
and CCR5. Lane 5 is CD4 and lane 6 is an mRNA-positive control for
CD4 from SupT1 T-cells. Lanes 7 and 8 show transcripts for DC-SIGN
and L-SIGN. The size of each amplicon was further confirmed with the
expected product size by Southern blotting. The hybridization probe for
each amplicon spans the internal sequences of the amplicon. A 100-bp
ladder-low from GenSura Laboratories (San Diego, CA) was used as a
DNA size marker. This figure is representative of three independent
studies.
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suggesting mainly the presence of macrophage-tropic
HIV-1 in human CSF and various CNS-based cells in vivo
(Reddy et al., 1996).
The above-described findings strongly suggest that
chemokine receptors are clearly expressed in primary
isolated human brain MVECs. None of these receptors
FIG. 3. (A) Immunofluorescencemicroscopy of primary isolated human brainMVECs for chemokine receptors. Primary isolated human brainMVECswere
plated on two-well chamber slides and allowed to grow for 48 h. The cells were fixed with 3.5% formaldehyde and incubated with primary antibodies directed
against respective chemokine receptors. Monoclonal antibodies were used for CCR3 (7BII), CXCR4 (12G5), CCR5 (2D7), and von Willebrand factor (Sigma).
The secondary antibody used with the von Willebrand factor primary antibody is shown in red (Cy3); CCR3, CXCR4, and CCR5 were detected by Cy2
secondary antibodies and are shown in green. Both Cy2 and Cy3 were obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). This
figure is representative of three independent experiments. (B) Immunocytochemical analysis of brain MVECs for APJ and DC-SIGN. Anti-human APJ antibody
was used to detect APJ in primary human brain endothelial cells. For detection of DC-SIGN, polyclonal antisera, kindly provided by Dr. Robert Dom’s
laboratory, University of Pennsylvania, were utilized. This figure is representative of two independent studies.
FIG. 4. Binding assays with cognate ligands for specific receptors. Effects of chemokines and polyclonal antisera on diverse HIV-1 strains’
attachment to primary brain MVECs. Brain MVECs, actively growing in 6-well plates, were preincubated with the individual chemokines/polyclonal
antisera, as shown, for 60 min. Plates were then incubated with normalized and equal quantities of HIV-1 p24 antigen (1.5 ng) equivalents for each
indicated virus for 3 h. After 3 h, the cells were vigorously washed with 1 PBS and lysed with 0.5% Triton-X 100, and cell-associated HIV-1 p24 antigen
was quantified via ELISA (Dupont). These findings are representative of two independent experiments.
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individually appears to be involved in HIV-1 attachment
to the surface of these human BBB-associated cells.
DISCUSSION
The molecular mechanisms involved in HIV-1 binding
to BBB-associated cells and entry into CNS remain enig-
matic. CD4-independent, chemokine receptor-depen-
dent infection and entry of SIV into simian capillary
endothelial cells have been reported previously (Edinger
et al., 1997a,b, 1998; Reddy et al., 1996). These data are
further supported by our current results suggesting that
CD4 is not detected on primary human brain MVECs, by
RT-PCR as well as immunofluorescence microscopy as-
says. However, both CXCR4 and CCR5 are expressed on
primary human brain MVECs, supporting their potential
role in HIV-1 entry. Nevertheless, the present viral bind-
ing assays showed that none of the chemokine receptor
ligands individually blocks HIV-1 attachment, suggesting
that an alternative receptor or a cooperative action of
known receptors is involved in viral attachment and en-
try.
The BBB consists mainly of microvascular endothelial
cells and astrocytic foot processes and separates the
CNS from the periphery (Joseph et al., 1997; Mukhtar and
Pomerantz, 1998; Rubin and Staddon, 1999). One of the
major functions of the BBB is to ensure a constant inter-
nal environment for proper synaptic transmission and
supply of essential nutrients for CNS-resident cells. This
structure is continuously exposed to a variety of inflam-
matory cells, as well as infections in the body fluids.
HIV-1 frequently infects the CNS of individuals soon
after seroconversion (Resnick et al., 1988; Spector et al.,
1993). Initial studies have demonstrated that microglia
and monocytes/macrophages are major cellular reser-
voirs for productive HIV-1 infection in the CNS (Bell et al.,
1993; Kure et al., 1990; Pumarola-Sune et al., 1987). A
number of studies have also demonstrated limited rep-
lication of HIV-1, in vivo as well as in vitro, within MVECs,
astrocytes, and neuronal elements utilizing immuno-
chemistry and in situ polymerase chain reaction (Bag-
asra et al., 1996; Mukhtar and Pomerantz, 2000; Nuovo
and Alfieri, 1996; Nuovo et al., 1994). It is a well accepted
that highly infectious mononuclear cells, especially HIV-
1-infected activated CD4 T-cells, traverse the neural
parenchyma and are probably much more efficient at
delivering virus to perivascular macrophages in the
brain. However, even a minor infection of brain MVECs
may play a major role in compromising the BBB and
easing the entry of free as well as cell-associated virus
into the brain. Recent studies, showing differential cyto-
kine and chemokine responses during neurological dis-
eases induced by retroviruses, also suggest the poten-
tial role of chemokines and their cognate receptors in the
neuropathogenesis of viral infections (Peterson et al.,
2001).
HIV-1 infection leads to a number of neurodegenera-
tive disorders in AIDS patients. In the model of rhesus
macaques infected with SIV, neurological disease man-
ifestations correlate with replicative capacity of viral
strains, as well as viral load in brain parenchyma (De-
muth et al., 2000; Rausch and Davis, 2001; Rausch et al.,
1994, 1999; Zink et al., 1998, 1999), but the detailed
neuropathogenesis of HIV-1 as well as SIV remains
somewhat elusive.
Our present data and a number of other laboratory’s
findings suggest that primary isolated human brain
MVECs are devoid of CD4 (Banks et al., 1998). Moreover,
it has also been suggested that CXCR4 on a variety of
human endothelial cells can serve as the receptor for
HIV-1 in the absence of CD4 (Molino et al., 2000). Re-
garding CCR5, another predominant chemokine receptor
facilitating the entry of R5 HIV-1 isolates, there are only a
few reports suggesting CD4-independent, CCR5-depen-
dent entry, though simian brain capillaries appear to be
devoid of CD4 receptor and utilize a CCR5-mediated
entry mechanism (Edinger et al., 1997a,b, 1998). It has
also been reported that CNS microglia express and uti-
lize both CCR3 and CCR5 for infection of the CNS by
HIV-1 (He et al., 1997).
Higher expression of the chemokine receptor CXCR4
on primary isolated brain MVECs suggests a major role
for this moiety in either signaling or viral entry. Most of
the HIV-1 brain isolates show an R5 phenotype, suggest-
ing CCR5-mediated entry/infection in CNS cells. Re-
cently, it has been reported that HIV-1 isolates from brain
and lymphoid tissues predict neurotropism independent
of coreceptor specificity (Gorry et al., 2001). Of note,
CD4/CXCR4-independent infection of CNS-based cells
by a T-tropic strain of HIV-1 has also been reported,
suggesting alternative entry mechanisms irrespective of
well-described chemokine receptors (Schweighardt et
al., 2001). These observations suggest certain previously
unknown or cooperative actions of various chemokine
receptors for entry/infection of CNS-based cells.
Recently, it has been shown that DC-SIGN as well as
L-SIGN serve as an attachment factor for HIV-1 on cell
membranes (Geijtenbeek et al., 2000a,b; Pohlmann et al.,
2001). Moreover, DC-SIGN/L-SIGN-attached virus could
exist stably bound or endocytosed. We identified cDNA
regions in DC/L-SIGN which can be utilized to study
differential expression of these genes (Fig. 2). Our stud-
ies also show that primary isolated human MVECs ex-
press both DC-SIGN and L-SIGN. As far as their role in
viral attachment and entry into brain MVECs is con-
cerned, we were unable to block the viral attachment on
MVECs with polyclonal DC-SIGN antiserum. Currently,
there is no potential DC/L-SIGN inhibitor available that
could be utilized to completely discern the role of DC/L-
SIGN expression on human brain MVECs; however,
these ligands and their role in viral attachment/entry are
vigorously being explored. The availability of potential
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DC/L-SIGN inhibitors will also assist in understanding
these ligands’ expression on MVECs.
As stated above, chemokine receptors are seven-
transmembrane domain, G-protein-coupled molecules
that have drawn much attention in the recent past for
their involvement in HIV-1 and SIV entry (Alkhatib et al.,
1996; Choe et al., 2000; Feng et al., 1996). Chemokines
and their cognate receptors are also involved in the
pathogenesis of immune-mediated inflammation of the
CNS that controls leukocyte migration across brain en-
dothelium, along with activation and movement of cells
within the brain parenchyma (Baggiolini, 1998). In addi-
tion to these rapidly accumulating data on chemokines,
there have been a number of reports evaluating chemo-
kine-receptor expression in CNS-based cells. Various
splicing patterns for chemokine-receptor isoforms (e.g.,
CXCR-4) have been found in mammalian astrocytes
(Heesen et al., 1997). Antigenetically, distinct conforma-
tions of CXCR4 further elaborate the hypothesis regard-
ing the existence of multiple conformations of these
coreceptors for viral entry (Baribaud et al., 2001). CXCR-4
has also been demonstrated to be present on both mi-
croglia and astrocytes, initially in the mouse and rat
(Heesen et al., 1997; Tanabe et al., 1997).
Among several other chemokine receptors, the role of
APJ, also a seven-transmembrane chemokine receptor
utilized for HIV-1 entry, is being explored. APJ shows
higher efficiency for entry of X4 and R5X4 HIV-1 strains
compared with R5 isolates (Edinger et al., 1998). This
coreceptor is highly expressed on the human neuronal
precursor cell line (NT2)-generated postmitotic neurons,
microglia, and oligodendrocytes (Choe et al., 2000;
Edinger et al., 1998). A potential ligand for APJ, Apelin-36,
with inhibitory activity for viral entry of primary T-cell-line-
tropic (CXCR4) and dual-tropic (CXCR4 and CCR5) HIV-1
isolates has been recently described (Cayabyab et al.,
2000; Zou et al., 2000). Of note, though, the inhibitory
activity was studied only in cells expressing both CD4
and APJ.
Expression of various chemokine receptors and a
number of other ligands on human brain MVECs is quite
intriguing, as the BBB consists mainly of microvascular
endothelial cells and is the first line of defense against
viral entry into the brain. The presence of chemokine
receptors and DC-SIGN/L-SIGN on BBB cellular constit-
uents suggests the potential for these cells to attach to
and endocytose HIV-1/SIV particles. Circulating HIV-1/
SIV could utilize MVEC DC-SIGN/L-SIGN, protecting it
from degradation and inactivation by immune regulatory
cells. It has already been reported that DC-SIGN-bound
HIV-1 has the advantage of increased stability and via-
bility (Geijtenbeek et al., 2000a,b). In a suitable environ-
ment, the MVEC-bound virus could enter the brain via
capillary endothelial cells. Although these results are in
conformity with our data and data from a number of other
laboratories suggesting retroviral infection of endothelial
cells, we were still unable to block viral attachment on
MVECs with ligands for APJ, CCR3, CXCR4, and CCR5.
This suggests the possibility of some alternative recep-
tors, such as proteoglycans (e.g., syndecans) or interac-
tion of chemokine receptors with syndecan-like mole-
cules (Saphire et al., 2001; Valenzuela-Fernandez et al.,
2001). Further studies are necessary to detect the critical
receptor(s) involved in penetration of the CNS by HIV-1/
SIV in vivo.
In summary, the present results reveal that primary
isolated human brain MVECs express a number of rele-
vant chemokine receptors. The role of each chemokine
receptor in viral entry has been elaborated previously.
Expression of DC-SIGN and L-SIGN suggests the poten-
tial for primary brain MVECs to bind and protect HIV-1 on
their membrane, as described earlier, in that DC-SIGN-
bound virus is quite stable and infectious. It is hypothe-
sized that under in vivo conditions circulating HIV-1 acts
as an opportunistic pathogen, binds to brain microvas-
culature, and later, when the BBB is breached under the
influence of various stimuli, enters the CNS parenchyma.
MATERIALS AND METHODS
Primary cells
Human brain MVECs were obtained from Cell System
Corp. (Kirkland, WA). These cells are fed at 48-h intervals;
however, when they reach 50% confluency they are fed
every 24 h. It is essential to prewarm growth medium to
37°C for feeding the cells. These cells also required
remarkably strict attention to proper conditions for in
vitro culture. The passage reagents, trypsin/EDTA, EDTA,
and the growth medium, must be warmed to 37°C. Ice-
cooled trypsin inhibitor solution is used. (1) MVECs at
80% confluency are washed with EDTA solution. (2) The
EDTA is replaced with a trypsin/EDTA mixture for 1 min.
(3) Immediately the trypsin-inhibitor solution is added
when the cells are dislodged from the flask surface; the
supernatant is disposed and the pellets are suspended
in prewarmed growth medium. (4) The cell suspensions
are added to culture flasks precoated with attachment
factor; precoating involves addition of attachment factor
(AF) to the flask and wetting the whole surface with the
AF. (5) The cells are incubated at 37°C, 5% CO2, 100%
humidity in human endothelial growth medium (Cell Sys-
tem Corp.). The purity of the cells is analyzed by immu-
nofluorescence staining with antibody to von Willebrand
factor, according to a previously described protocol
(Mukhtar and Pomerantz, 2000).
Antibodies and chemokines
Anti-human von Willebrand factor and monoclonal
anti-human CD4 were purchased from Sigma (St. Louis,
MO). Monoclonal anti-APJ and anti-human CCR5 anti-
bodies were purchased from R&D Systems (Minneapo-
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lis, MN). An aliquot of CCR3 monoclonal antibody (7B11)
was obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH (He et al.,
1997; Heath et al., 1997). Anti-CXCR4 (12G5) antibody
was a kind gift from Dr. James Hoxie’s laboratory, Uni-
versity of Pennsylvania (Philadelphia, PA). Polyclonal DC-
SIGN antiserum (1459) was kindly provided by Dr. Robert
Doms, University of Pennsylvania (Soilleux et al., 2002).
The chemokines, recombinant human MIP-1, MIP-1,
RANTES, eotaxin, and SDF-1, were purchased from
R&D Systems. APJ ligands Apelin-36 and Apelin-15 were
a kind gift from Dr. Shuju Hinuma of Takeda Chemical
Industries, Ltd., Ibaraki, Japan.
PCR primers and probes
A complete listing of PCR primers, probes, and ex-
pected amplicon sizes is detailed in Tables 1 and 2.
For selection of primers, we utilized Right Primer soft-
ware, according to previously described specifications
(Mukhtar and Bagasra, 1997). Of note, for DC-SIGN and
L-SIGN primer selections, cDNAs for these genes were
aligned to identify specific regions that could be utilized
to differentially amplify both of these genes. An align-
ment for these genes has been submitted to the Euro-
pean Molecular Biology Laboratory (EMBL) under Acces-
sion No. ALIGN_000098.
Reverse transcriptase-polymerase chain reactions
Total cellular RNA from third-passage human brain
MVECs was isolated by using the ULTRASPEC RNA
Isolation System (Biotecx Laboratories, Inc., Houston,
TX), according to the manufacturer’s instructions. The
integrity of total RNA was confirmed on an agarose gel.
For cDNA synthesis, 4 g of total RNA was primed with
oligo(dT) and reverse-transcribed in a 30-l reaction
mixture utilizing the Sigma RT-PCR kit, according to the
manufacturer’s recommendations. Five microliters of
cDNA was subjected to hot-start PCR amplification by
using Taq polymerase. PCR conditions were an initial
hot-start for 5 min at 94°C followed by 35 cycles of
denaturing at 94°C for 45 s, annealing at 56°C for 45 s,
and extension at 72°C for 1 min with a final extension at
72°C for 10 min. Both sense and antisense primers used
for amplification of each receptor and amplicon size are
shown in Table 1.
Viral stocks
The viral stocks used for infection of primary brain
MVECs were produced by transfection of 293T cells with
respective proviral DNA, as described previously (Oha-
gen et al., 1999). Briefly, 48 h after calcium transfection of
proviral DNA, supernatant was collected, filtered through
a 0.45-m-pore-size filter, quantified by HIV-1 p24 anti-
gen enzyme-linked immunosorbent assay (ELISA), and
stored at 70°C for further utilization. The viral strains
used in these studies were NL4-3, an X4-tropic strain,
Bal, an R5-tropic strain, and 89.6, an X4R5-tropic strain.
Among these, NL4-3 utilizes CXCR4 as a major corecep-
tor, whereas R5 entry is mediated by CCR5, and dual-
tropic strains use both CXCR5 and CCR5 for viral entry
and infection.
Treatment of primary human brain MVECs with
receptor ligands and HIV-1 p24 antigen-binding
assays
Binding of viral particles to human brain MVECs was
assessed by measuring cell-associated HIV-1 p24 anti-
gen levels. Third-passage primary isolated human brain
MVECs were seeded in 12-well plates and allowed to
attach for 48 h. After 48 h, approximately 80% confluent
brain MVECs were exposed to chemokine receptor li-
gands Eotaxin (500 ng/ml), SDF1- (2.5 g/ml), RANTES,
MIP-1-, and MIP-1- (500 ng/ml each), or Apelin-36 and
Apelin-15 (120 M). For CD4 blocking, soluble CD4 (20
g/ml) was used, and 1:5 diluted polyclonal DC-SIGN
antiserum was used for DC-SIGN blocking. After 60 min,
each of the ligand solutions was decanted and the cells
were exposed to 1.5 ng of p24 antigen equivalents of X4
(NL4-3), R5 (Bal), and X4R5 (89.6) viral strains in inde-
pendent wells, with a control lacking all of the above
ligands. After 3 h, the unbound virus was thoroughly
washed off with 1 phosphate-buffered saline (PBS),
and then the cells were lysed with Triton-X 100 and
analyzed with HIV-1 p24 antigen ELISA (Dupont).
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